Skip to site menu Skip to page content

Daily Newsletter

11 August 2023

Daily Newsletter

11 August 2023

Healthtech company Capital Rx receives investment from Memorial Hermann

This investment will support the development of JUDI, a cloud-native enterprise pharmacy platform.

August 11 2023

Texas-based non-profit health provider Memorial Hermann Health System has invested in Capital Rx, a US health technology company offering pharmacy benefit management (PBM) solutions.

The investment amount was not disclosed.

This investment is expected to support the development of JUDI, a cloud-native enterprise pharmacy platform.

Introduced in 2021, the platform integrates all PBM operations into one platform. The operations unified by the tool include claim adjudication, data integration, underwriting, patient communication, client reporting, reimbursement, and invoicing, among others.

The solution uses serverless architecture, which is said to help manage customers of any size and enable scalability.

The tool currently caters to more than 2.4 million Medicare, Medicaid, and commercial plan members. 

Memorial Hermann executive vice-president and chief strategy officer Feby Abraham said: "As we assessed the healthcare ecosystem for innovative capabilities to help accelerate the evolution of the pharmacy service model and prescription claims processing, Capital Rx's vision for a framework that prioritises efficiency and allows for exceptional patient care set the company apart for investment consideration.

“Capital Rx's platform is focused on bringing clarity and consistency to drug prices, broadening access to medication, and helping its clients control pharmacy costs, all without sacrificing member service and patient outcomes.”

Capital Rx co-founder and CEO AJ Loiacono said: "We're thrilled to have the investment support of Memorial Hermann as we work to modernise this country's claims processing infrastructure and deploy our aligned customer model to more employers, unions, municipalities, and other payers to create enduring change.”

Healthcare companies are hesitant to invest in the metaverse

The COVID-19 pandemic pushed the healthcare industry to rapid digitalization. Increased use of telehealth, telepresence systems, remote diagnostics, predictive AI, and wearable technology is changing how healthcare is delivered and improving patient outcomes. Emerging technologies such as AR and VR are becoming increasingly routine for professional training, surgical assistance, and treatment of psychological and neurological disorders. In the pharma and medical devices industries, AR, VR, and AI are rapidly accelerating drug discovery and manufacturing and generating supply chain efficiencies. New digital opportunities will look to build upon disruptive technologies. However, affordability is a limiting factor to widespread adoption. Per GlobalData estimates, the metaverse market is expected to grow at a CAGR of more than 33% between 2023 and 2030. Although metaverse technologies could reinvent healthcare approaches and bring new experiences to healthcare providers and patients, adoption is still at an early stage. There are currently few use cases in the healthcare industry. The metaverse needs to overcome major challenges for healthcare, including regulation and data privacy concerns. Evidence of proven use cases and participation by a critical mass of users are imperative to drive a shift in metaverse investment.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close